SciSparc Ltd. (SPRC)
SPRCNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.4001
-0.0339 (-7.81%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $855.0k
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.4088 to $29.88
- Average volume
- 1.67m
- Previous close
- $0.4340
Financials
| Quarter | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$505.0k | -$535.0k | -$560.0k | -$400.0k |
| Net income | -$519.0k | -$525.0k | -$572.0k | -$391.0k |
News
8 latest- SciSparc Ltd. Amends Form 6-K to Correct Floor Price to $0.11952Fintel · 8 hours ago
- SciSparc Ltd. Enters Inducement Agreement to Exercise Warrants for $405,728Fintel · Oct 26, 2026
- SciSparc Ltd. Subsidiary NeuroThera Labs Reports Progress in Phase IIb Clinical Trial for Tourette SyndromeFintel · Oct 23, 2026
- SciSparc Prepares For Patient Enrollment In Phase IIb Tourette Syndrome Study RTTNews · Oct 22, 2026
- Biotech Stocks In Focus - SXTC +536% On Sharp Move; VRXA, AVBP, SPRC On Key Developments RTTNews · Oct 7, 2026
- SciSparc Reports Quantum-Enabled Gene Analysis Acceleration RTTNews · Oct 7, 2026
- Clearmind Reports U.S. Patent Applications For Drug Combinations In Mental Health RTTNews · Sep 26, 2026
- SciSparc Subsidiary Pursues FDA Orphan Drug Status For Tourette Syndrome Drug RTTNews · Sep 2, 2026
The company
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- scisparc.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.